27 results

  • advair

    (fluticasone propionate and salmeterol)
    GlaxoSmithKline LLC
    ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 and older and for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or for patients not adequately controlled on long-term asthma medications.

  • advair hfa

    (fluticasone propionate and salmeterol xinafoate)
    GlaxoSmithKline LLC
    ADVAIR HFA is indicated for the treatment of asthma in adults and adolescents aged 12 and older who are not adequately controlled on long-term asthma medications or require both an inhaled corticosteroid and a long-acting beta2-adrenergic agonist. It is not for acute bronchospasm relief.

  • anoro ellipta

    (umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

  • arnuity ellipta

    (fluticasone furoate)
    GlaxoSmithKline LLC
    ARNUITY ELLIPTA is indicated for the maintenance treatment of asthma in adults and children aged 5 years and older, but is not intended for the relief of acute bronchospasm.

  • benlysta

    (belimumab)
    GlaxoSmithKline LLC
    BENLYSTA (belimumab) is indicated for patients aged 5 and older with active systemic lupus erythematosus and active lupus nephritis, both receiving standard therapy. Its efficacy in severe active central nervous system lupus is not evaluated, hence it is not recommended for such cases.

  • blujepa

    (gepotidacin)
    GlaxoSmithKline LLC
    BLUJEPA is indicated for treating uncomplicated urinary tract infections in female patients aged 12 and older, caused by susceptible bacteria such as E. coli and Klebsiella pneumoniae. It should be used selectively to reduce drug-resistant bacteria and maintain the effectiveness of antibacterial agents.

  • breo ellipta

    (fluticasone furoate and vilanterol trifenatate)
    GlaxoSmithKline LLC
    BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not to be used for the relief of acute bronchospasm.

  • flolan - epoprostenol sodium injection, powder, lyophilized, for solution

    (Epoprostenol Sodium)
    Glaxosmithkline Llc

  • imitrex

    (sumatriptan)
    GlaxoSmithKline LLC
    IMITREX injection is indicated for the acute treatment of migraine and cluster headache in adults. It should only be used with a confirmed diagnosis, and is not intended for the prevention of these headaches. If there is no response to initial treatment, the diagnosis should be re-evaluated.

  • imitrex

    (sumatriptan)
    GlaxoSmithKline LLC
    IMITREX tablets are indicated for the acute treatment of migraine with or without aura in adults. It is not for migraine prevention or for treating cluster headaches, and should only be used if a clear migraine diagnosis is established.